Somrudee Reabroi

สมฤดี เรียบร้อย

Instructor
+662-201-5641-2
+662-354-7157
somrudee.rea@mahidol.ac.th
Education
  • B.Sc. (Pharmaceutical Science) Ubonratchathani University, Thailand
  • Ph.D. (Physiology) Mahidol University, Thailand
Current Research
  • Anticancer drug discovery
  • Cancer biology
  • Protein degradation in cancers
  • ER stress-mediated signaling pathway

 

Publications
  • Tohkayomatee R, Reabroi S, Tungmunnithum D, Parichatikanond W, Pinthong D*. Andrographolide exhibits anticancer activity against breast cancer cells (MCF-7 and MDA-MB-231 cells) through suppressing cell proliferation and inducing cell apoptosis via Inactivation of ER-α receptor and PI3K/AKT/mTOR signaling. Molecules 2022 May 31;27(11):3544.
  • Maijaroen S, Klaynongsruang S, Reabroi S, Chairoungdua A, Roytrakul S, Daduang J, Taemaitree L, Jangpromma N*. Proteomic profiling reveals antitumor effects of RT2 peptide on a human colon carcinoma xenograft mouse model. Eur J Pharmacol 2022 Feb;917:174753.
  • Jampasri S, Reabroi S, Tungmunnithum D, Parichatikanond W, Pinthong D*. Plumbagin suppresses breast cancer progression by downregulating HIF-1α expression via a PI3K/Akt/mTOR independent pathway under hypoxic condition. Molecules 2022 Sep;27(17):5716.
  • Suksen K, Janpipatkul K, Reabroi S, Anantachoke N, Reutrakul V, Chairoungdua A, Thongon N, Bhukhai K*. Gambogic acid inhibits Wnt/β-catenin signaling and induces ER stress-mediated apoptosis in human cholangiocarcinoma. Asian Pac J Cancer Preven 2021 Jun;22(6):1913-20.
  • Kumari N, Reabroi S, North BJ*. Unraveling the molecular nexus between GPCRs, ERS, and EMT. Mediat Inflamm 2021 Mar;2021:6655417.
  • Mazumder A, Assawapanumat W, Dwivedi A, Reabroi S, Chairoungdua A, Nasongkla N*. Glucose targeted therapy against liver hepatocellular carcinoma: In vivo study. J Drug Deliv Sci Technol 2019 Feb;49:502-512.
  • Mazumder A., Assawapanumat W., Dwivedi A., Reabroi S., Chairoungdua A. & Nasongkla N. (2019). Glucose targeted therapy against liver hepatocellular carcinoma: In vivostudy, J Drug Deliv Sci Tech, 49: 502-512.
  • Reabroi S., Saeeng R., Boonmuen N., Kasemsuk T., Saengsawang W., Suksen K., Zhu W., Piyachaturawat P. & Chairoungdua A. (2018). The anti-cancer activity of an andrographolide analogue functions through a GSK-3β-independent Wnt/β-catenin signaling pathway in colorectal cancer cells. Sci Rep, 8: 1-14.
  • Reabroi S., Chairoungdua A., Saeeng R., Kasemsuk T., Saengsawang W., Zhu W. & Piyachaturawat P. (2018). A silyl andrographolide analogue suppresses Wnt/β-catenin signaling pathway in colon cancer. Biomed Pharmacother, 101: 414-421.
  • Puntawee S., Theerasilp M., Reabroi S., Saeeng R., Piyachaturawat P., Chairoungdua A. & Nasongkla N. (2015). Solubility enhancement and in vitro evaluation of PEG-b-PLA micelles as nanocarrier of semi-synthetic andrographolide analogue for cholangiocarcinoma chemotherapy. Dev. Technol.4: 1-8.
  • Nateewattana J., Dutta S., Reabroi S., Saeeng R., Kasemsook S., Chairoungdua A., Weerachayaporn J., Wongkham S. & Piyachaturawat P. (2014). Induction of apoptosis in cholangiocarcinoma by an andrographolide analogue is mediated through topoisomerase II alpha inhibition. J. Pharmacol. 723: 148-155.